These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 21438803)

  • 1. Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug development.
    Bays HE
    Expert Rev Cardiovasc Ther; 2011 Mar; 9(3):265-77. PubMed ID: 21438803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease.
    Bays HE
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1429-45. PubMed ID: 19900026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lorcaserin. In obesity: unacceptable risks.
    Prescrire Int; 2014 May; 23(149):117-20. PubMed ID: 24926508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lorcaserin: an investigational serotonin 2C agonist for weight loss.
    Hurren KM; Berlie HD
    Am J Health Syst Pharm; 2011 Nov; 68(21):2029-37. PubMed ID: 22011982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lorcaserin for weight loss: insights into US Food and Drug Administration approval.
    Miller LE
    J Acad Nutr Diet; 2013 Jan; 113(1):25-30. PubMed ID: 23260720
    [No Abstract]   [Full Text] [Related]  

  • 6. Multicenter, placebo-controlled trial of lorcaserin for weight management.
    Smith SR; Weissman NJ; Anderson CM; Sanchez M; Chuang E; Stubbe S; Bays H; Shanahan WR;
    N Engl J Med; 2010 Jul; 363(3):245-56. PubMed ID: 20647200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.
    Bays H
    Expert Rev Cardiovasc Ther; 2010 Dec; 8(12):1777-801. PubMed ID: 20707765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety and efficacy of lorcaserin in the management of obesity.
    Hess R; Cross LB
    Postgrad Med; 2013 Nov; 125(6):62-72. PubMed ID: 24200762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial.
    Fidler MC; Sanchez M; Raether B; Weissman NJ; Smith SR; Shanahan WR; Anderson CM;
    J Clin Endocrinol Metab; 2011 Oct; 96(10):3067-77. PubMed ID: 21795446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The new weight-loss drugs, lorcaserin and phentermine-topiramate: slim pickings?
    Woloshin S; Schwartz LM
    JAMA Intern Med; 2014 Apr; 174(4):615-9. PubMed ID: 24515599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The FDA's assessment of two drugs for chronic weight management.
    Colman E; Golden J; Roberts M; Egan A; Weaver J; Rosebraugh C
    N Engl J Med; 2012 Oct; 367(17):1577-9. PubMed ID: 23050510
    [No Abstract]   [Full Text] [Related]  

  • 12. Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials.
    Weissman NJ; Sanchez M; Koch GG; Smith SR; Shanahan WR; Anderson CM
    Circ Cardiovasc Imaging; 2013 Jul; 6(4):560-7. PubMed ID: 23661689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and tolerability review of lorcaserin in clinical trials.
    Greenway FL; Shanahan W; Fain R; Ma T; Rubino D
    Clin Obes; 2016 Oct; 6(5):285-95. PubMed ID: 27627785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New antiobesity agents: lorcaserin (Belviq) and phentermine/topiramate ER (Qsymia).
    Shyh G; Cheng-Lai A
    Cardiol Rev; 2014; 22(1):43-50. PubMed ID: 24304809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug management of obesity--efficacy versus safety.
    Astrup A
    N Engl J Med; 2010 Jul; 363(3):288-90. PubMed ID: 20647205
    [No Abstract]   [Full Text] [Related]  

  • 16. Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women.
    Smith SR; Prosser WA; Donahue DJ; Morgan ME; Anderson CM; Shanahan WR;
    Obesity (Silver Spring); 2009 Mar; 17(3):494-503. PubMed ID: 19057523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity.
    Nigro SC; Luon D; Baker WL
    Curr Med Res Opin; 2013 Jul; 29(7):839-48. PubMed ID: 23574263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lorcaserin approval in the United States: paving the way?
    Pedersen SD; Astrup A
    Endocrinol Nutr; 2012 Nov; 59(9):521-2. PubMed ID: 22939712
    [No Abstract]   [Full Text] [Related]  

  • 19. Two anti-obesity hopefuls and their safety.
    Bello NT; Campbell SC
    Expert Opin Drug Saf; 2012 Sep; 11(5):681-3. PubMed ID: 22788876
    [No Abstract]   [Full Text] [Related]  

  • 20. New obesity agents: lorcaserin and phentermine/topiramate.
    Fleming JW; McClendon KS; Riche DM
    Ann Pharmacother; 2013; 47(7-8):1007-16. PubMed ID: 23800750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.